Sponsored

Ensuring Efficacy and the Launch of a New Bioactive, CBG

Demetrix Gci2205 Lead

Untapped bioactive ingredients offer new opportunities for formulators to introduce innovative cosmetics and personal care products to the world. While innovation is exciting, new ingredients can also bring about safety concerns and questions for consumers, who are already paying close attention to how ingredients are sourced, their effect on the planet and biological activity. If safety and safety testing isn’t top of mind for manufacturers, they risk recall by regulatory agencies, rejection in the marketplace and (potentially) unnecessary harm to people.

Our company, Demetrix, recently announced the commercial-scale launch of a new bioactive ingredient, Arete-G™, which is our exclusive CBG, a rare cannabinoid found in the cannabis sativa plant. Reaching this major milestone required our team to address some of the safety concerns surrounding cannabinoids, as cases of contaminated CBD-containing products have been highly publicized. Arete-G does not have many of the contaminants present in traditional cannabinoid manufacturing processes that can cause skin health and formulation issues. And this is because we focused our efforts on using proprietary biotechnology to manufacture the highest quality product possible. 

CBG was tested for ocular irritation using in vitro studies including Bovine Corneal Opacity and Permeability (BCOP) assay and Chorioallantoic Membrane Vascular Assay (CAMVA). In both the BCOP assay and CAMVA, neither CBG formulation tested (10% CBG in caprylic/capric triglyceride or 1% CBG cream), was found to be an irritant. We also used the same CBG formulations to perform a Human Repeated Insult Patch Test (HRIPT) with 103 healthy volunteers and saw no evidence of skin sensitization.

Together, these tests demonstrate that Arete-G has a low potential for causing ocular irritation or contact dermatitis when applied topically. At Demetrix, we are dedicated to producing scalable supplies of rare cannabinoids, investigating cannabinoids for attractive bioactivities, and ensuring, for both manufacturers and consumers, that cannabinoid-containing formulations are safe. 

Disclaimer:

The above paid-for content was produced by and posted on behalf of the Sponsor. Content provided is generated solely by the Sponsor or its affiliates, and it is the Sponsor’s responsi­bility for the accuracy, completeness and validity of all information included. Cosmetics & Toiletries takes steps to ensure that you will not confuse sponsored content with content produced by Cosmetics & Toiletries and governed by its editorial policy.

More in Home